Lisinopril

According to the FDA label: Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: • Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) • Adjunct therapy for heart failure (1.2) • Treatment of Acute Myocardial Infarction 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure.

291,488 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Lisinopril in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Lisinopril adverse event reports by reporter sex
SexReports
Female141,838
Male132,092
Unknown328

By Age Group

View age group data as a table
Lisinopril adverse event reports by reporter age group
Age groupReports
0-171,898
18-344,738
35-4923,517
50-6467,990
65-7452,115
75+42,499

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Lisinopril. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Lisinopril adverse event reports by reported outcome
OutcomeReports
Non-Serious114,754
Other Serious107,153
Hospitalization92,110
Death23,806
Life-Threatening12,997
Disability8,911

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Lisinopril. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Lisinopril adverse event reports by year
YearReports
20042,862
20053,787
20064,148
20074,264
20085,345
20097,306
201010,347
201110,676
201212,560
201312,112
201417,293
201521,707
201622,448
201721,228
201823,127
201922,371
202017,822
202115,514
202215,014
202313,018
202412,442
202513,274
2026 (partial)2,823

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Lisinopril

In FDA adverse event reports that mention Lisinopril, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026